Navigation Links
Amicus Therapeutics Announces Second Quarter 2009 Financial Results
Date:8/5/2009

is year.

As previously announced, the Phase 3 trial will evaluate the efficacy, safety, and pharmacodynamics of Amigal in males and females with Fabry disease. The trial will consist of a six-month double-blind, randomized, placebo-controlled treatment stage and will enroll approximately 60 subjects who are naive to enzyme replacement therapy (ERT) or who have not received ERT for at least six months prior to the start of treatment with Amigal. The Amigal treatment arm dose and regimen will be 150 mg every other day.

The primary endpoint will be the change in the amount of kidney interstitial capillary GL-3 as measured in kidney biopsies using histology. Secondary endpoints will include safety and tolerability, kidney GL-3 as measured in urine, and an assessment of renal function (including glomerular filtration rate (GFR) and 24-hour urine protein).

Additionally, the FDA and Amicus reached agreement on an improved methodology for the histological evaluation of GL-3 in the kidney biopsies. An analysis of the Phase 2 and Phase 2 extension study biopsies using the improved methodology demonstrated that all of the evaluable baseline samples had detectable interstitial capillary GL-3 and that reductions were observed in eight of the nine responders.

It is expected that approximately 30 clinical sites worldwide will participate in this trial.

Plicera(TM) (afegostat tartrate) for the treatment of Gaucher Disease

A Phase 2 clinical trial of the Company's investigational drug Plicera is ongoing. This 6-month study is designed to evaluate safety, dosing, and preliminary efficacy, as measured by the standard endpoints in Gaucher disease. The Company expects to report the results early in the fourth quarter of 2009.

Amicus continues to work closely with its partner, Shire HGT, to prepare for Phase 3 development
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... OMICS Group’s 5th International conference and ... 2014 at Double Tree by Hilton Beijing, China is ... Analytical & Bioanalytical research methods only to facilitate improved ... occasion, Dr. Srinubabu Gedela, MD of OMICS Group Inc ... remarkable one in bringing a unique and international mix ...
(Date:7/10/2014)... 2014 Senior supply chain management executives ... addressed the challenges of “Reducing Cost, Lead Time, & ... strategic sourcing. Describing the partnership of the Bio Supply ... Management Institute ( SCMI) of the University of ... at the Kroc Institute of Peace and Justice in ...
(Date:7/10/2014)... PETERSBURG, Russia , July 10, 2014 ... Russian Federation Dmitry Medvedev , presented ... biopharmaceutical company BIOCAD . The Company is developing ... scope of MabNext project BIOCAD develops a number of ... cancer and autoimmune diseases. The ceremony took place at ...
(Date:7/10/2014)... , July 10, 2014 /PRNewswire-iReach/ -- Tute ... interpretation, today announced an agreement with Lineagen, ... for Lineagen,s NextStep Dx PLUS.  Lineagen, ... and neurological disorders, currently offers FirstStep Dx ... testing service used by healthcare providers as ...
Breaking Biology Technology:A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4
... May 21 Oncolab, Inc.,s AMAS(R) Test,( http://www.oncolabinc.com ... may,allow early detection of a wide range of ... Anti-malignin antibody, in human,serum., Anti-malignin is a ... to,increase with age, as the risk of cancer ...
... ERES ), a leading provider of centralized,electrocardiographic ... Michael J. McKelvey, the Company,s President and,Chief Executive ... are scheduled to present at the FBR 12th ... May 28, 2008 at the Grand Hyatt Hotel ...
... Calif., May 20 NASA has,developed a revolutionary ... bacteria, viruses and parasites. This biosensor,will be used ... biohazards in,water, food and other contaminated sources., ... California licensed the,biosensor technology to Early Warning Inc., ...
Cached Biology Technology:eResearchTechnology to Present at the FBR 12th Annual Spring Investor Conference on May 28th 2008 2NASA Nanotechnology-Based Biosensor Helps Detect Biohazards 2
(Date:7/10/2014)... Fingerprint Cards, (FPC,s) new mobile touch ... A Chinese Top 5 smartphone OEM has selected FPC1021 for ... in October 2014.   FPC is proud to ... which has a planned date for the start of mass ... this phone of 3 million units. The Chinese OEM wants ...
(Date:7/10/2014)... Fingerprint Cards, (FPC,s) new ... (DW). An Asian OEM has selected FPC1021 for a flagship ... August 2014.   FPC is proud to announce ... planned date for start of mass production in August 2014. ... 5M, for delivery in the first half of July. The ...
(Date:7/10/2014)... 2014 The widespread adoption of the ... by meaningful use and related federal programs, is ... laboratory information. Now, more than ever, pathologists need ... informatics in order to deliver high quality and ... educational needs of pathologists in this evolving health ...
Breaking Biology News(10 mins):FPC Wins DW for 1021 Touch Sensor for Flagship Smartphone from Chinese Top 5 Smartphone OEM 2FPC Wins DW and Initial Ramp Order for FPC1021 Touch Sensor for Flagship Smartphone from Asian OEM 2New Clinical Informatics Curriculum Prepares Future Pathologists 2New Clinical Informatics Curriculum Prepares Future Pathologists 3New Clinical Informatics Curriculum Prepares Future Pathologists 4
... dramatic increases in children requiring medical intervention, although the ... low. The Annals of Emergency Medicine ... January 2005 through December 2011 will be published online ... Marijuana in the U.S."). "We believe that ...
... of volatile organic compounds from Earth,s forests and smoke ... greater impact on global warming than ancient atmospheric levels ... The research provides evidence that dynamic atmospheric chemistry played ... complexity of climate change and the relevance of natural ...
... , PROVIDENCE, R.I. [Brown University] For years, researchers ... Indy (for "I,m Not Dead Yet") affect metabolism, life ... flies. So far mutations in Indy have been studied ... study reports that a particularly important variation of the ...
Cached Biology News:Decriminalizing pot may land more kids in the ER 2Forest emissions, wildfires explain why ancient Earth was so hot 2Forest emissions, wildfires explain why ancient Earth was so hot 3Longevity mutation found in flies far and wide 2Longevity mutation found in flies far and wide 3
The Proteome Profiler Human Phospho-MAPK Array Kit contains 4 membranes - each spotted in duplicate with 23 different MAPK antibodies....
Mycoplasma tested...
Recombinant Human PTP1B (aa 2-321), CF...
Request Info...
Biology Products: